News

May 10 2023

Introducing SDMC Statistics Division Member, Eric Polley, Ph.D.

May 10 2023

Spotlight on the PSC Working Groups

May 10 2023

FORTE Study Update: May 2023

May 10 2023

Not Leaving Veterans Behind

May 10 2023

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (NRG-CC009)

May 10 2023

Should SRS be Delivered Before or After Surgery for Patients with Brain Metastases? (NRG-BN012)

April 28 2023

NRG Oncology Seeks to Fill the Position of Vice-Chair, NRG Oncology NCORP Cancer Control Committee

April 27 2023

Patient-Reported Outcomes from an NRG Oncology Study of Androgen Deprivation Therapy with Dose-Escalated Radiotherapy for Intermediate-Risk Prostate Cancer Show No Clinically Meaningful Differences in Scores at One Year Post-Treatment

April 27 2023

NRG Oncology Trial Does Not Improve Overall Survival, but Shows Improvements in Several Clinical Outcomes for Men with Intermediate-Risk Prostate Cancer

April 27 2023

NRG Oncology Study Results Confirm Conventional External Beam Radiotherapy Should Remain Standard of Care in Treating Localized Vertebral Metastases of the Spine

April 18 2023

Webinar: NRG-GI004 / SWOG S1610 COMMIT Study Amendment 9 Overview

April 12 2023

Show Me the Money

April 12 2023

FORTE at #NRG2023!

April 12 2023

Comparing Selumetinib and Olaparib to Selumetinib Alone for Ovarian and Endometrial Cancers with RAS Pathway Mutations (EAY191-N4, A ComboMATCH Treatment Trial)

April 12 2023

Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone-Receptor Positive Metastatic Breast Cancer (EAY191-N2, A ComboMATCH Treatment Trial)

April 12 2023

WVOCA Donates Additional Funds to the NRG Oncology Health Equity Fellowship Program

April 12 2023

PI Perspective: The Journey of NRG-GY018

April 12 2023

NRG Oncology and RTOG Foundation Integrated Efforts in the Head and Neck Cancer Committee

April 12 2023

Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-positive Salivary Gland Cancer (NRG-HN010)

April 06 2023

Webinar: Surgical Implications of ctDNA: Is this the future for colon cancer?

March 31 2023

NRG Oncology Combined Trial Long-Term Results Indicate that Pathologic Complete Response is Prognostic of Outcomes for Soft Tissue Sarcoma Patients

March 27 2023

Late-Breaking Results of NRG-GY018 Presented at SGO 2023: Study Demonstrates Improved PFS Outcomes with the Addition of Pembrolizumab to Chemotherapy for Women with Advanced or Recurrent Endometrial Cancer

March 26 2023

Study Identifies Two Promising Molecular Targets for Drug Development in Recurrent and Metastatic Cervical Cancer

March 25 2023

The Utilization of Atezolizumab as a Primer for Chemoradiation Results in Promising Immune System Alterations for Women with Locally Advanced Cervical Cancer

March 25 2023

The Addition of Gemcitabine with Cisplatin and Intensity-Modulated Radiation Therapy Improves Outcomes for Women with Locally Advanced Vulvar Cancer

March 15 2023

Circulating Tumor DNA: One of Our Newest Tools for Managing Solid Tumors

March 15 2023

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

March 15 2023

FORTE Study News: It’s Colorectal Cancer Awareness Month!

March 09 2023

RFAs for the NRG Early Career & New Investigators (ECNI) Committee AND for the NRG ECNI Mentored Fellowship

February 16 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

February 15 2023

NRG Oncology seeks to fill the position of Chair of the NRG Oncology Publications Committee

February 15 2023

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology Immunotherapy Subcommittee

February 15 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

February 15 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

February 14 2023

Protocol Support Committee (PSC) Column: NRG Oncology PSC 2023 Winter Meeting Wrap Up

February 14 2023

Initial Report on Establishing Working Groups within the Head and Neck Cancer Committee

February 14 2023

FORTE Study Update: Participant Travel Allowance

February 09 2023

NRG Oncology Selects Three Awardees for Health Equity Fellowship Program

February 03 2023

NRG Oncology NRG-GY018 Study Demonstrates Significantly Improved Progression Free Survival Outcomes for Women with Advanced or Recurrent Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy

January 18 2023

Set Up for Success - Coordinating RECIST 1.1: A Community Hospital Perspective

January 18 2023

#FORTEStudy Workshop

January 18 2023

NRG Innovations Continue in Cancer Care Delivery Research

January 18 2023

Adding Atezolizumab to Cisplatin and Radiotherapy for Node-Positive Locally Advanced Cervical Cancer (NRG-GY017)

January 18 2023

A Message from the NRG Oncology Research Strategy Committee Chairs: 2022: The Year in Review

January 18 2023

A Message from the NRG Oncology Group Chairs: 2022 in Review and a Look Ahead

December 19 2022

NRG Oncology Holiday Closures for 2022

December 12 2022

NRG Meeting PSC Information

December 12 2022

NRG-CC005/FORTE Site Implementation Guide: Part 1

December 12 2022

Julian Hong, M.D., M.S.: Steward of Cancer Care Delivery Research and Innovation

December 12 2022

NRG Oncology Announces Leadership of New Diversity, Equity, and Inclusion Committee, New Vice Chair for Ancillary Projects Committee

November 09 2022

Protocol Support Committee Column: NRG Best Practice Tool

November 09 2022

Dr. Jong H. Jeong Joins NRG Oncology SDMC

November 09 2022

#FORTEStudy is on YouTube!

November 09 2022

Assessing SBRT to the Primary Tumor Followed by Conventional Radiation Therapy with Concurrent Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

November 09 2022

Assessing the Addition of IMPRINT to Surgery and Systemic Therapy for Malignant Pleural Mesothelioma (NRG-LU006)

November 03 2022

NRG Oncology Patient Advocate Committee - Call for Candidates

October 24 2022

Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard

October 24 2022

NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research

October 24 2022

Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer

October 24 2022

The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival

October 12 2022

The Protocol Support Committee (PSC) Wants You!

October 12 2022

#FORTEStudy in Chicago!

October 12 2022

Comparing Docetaxel and Trastuzumab to Ado-Trastuzumab Emtansine for HER2-positive Salivary Gland Cancer (NRG-HN010)

October 12 2022

Assessing the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (NRG-CC010)

October 12 2022

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

October 12 2022

NRG-BR007 (“DEBRA”): A Phase III Clinical Trial Evaluating the De-escalation of Breast Radiation for a More Conservative Treatment of Patients With Low-Risk, Hormone-Sensitive, Node-Negative Breast Cancer

October 06 2022

NRG Oncology Appoints Chair & Vice Chair of Radiation Oncology Committee

September 26 2022

Foundation Accrual Credit for NRG Membership Requirements Announcement

September 21 2022

Intensity Modulated Radiotherapy Improved Patient-Reported Outcomes on NRG Oncology Clinical Trial

September 15 2022

In Memoriam: James Lloyd Hoehn, MD, FACS

September 15 2022

Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022

September 15 2022

NRG Health Equity Fellowship Call for Applications

September 15 2022

Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)

September 15 2022

Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

September 15 2022

NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer

September 15 2022

NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

September 15 2022

Testing the addition of trastuzumab or trastuzumab/pertuzumab to the usual chemotherapy for HER2 positive uterine serous or carcinosarcoma (NRG-GY026)

September 12 2022

NRG Oncology accepting applications for the position of Vice Chair, Ancillary Projects Committee

August 18 2022

NRG Oncology and The GOG Foundation Honor the Life of Mary "Dicey" Scroggins

August 12 2022

Summer Meeting 2022 Protocol Support Committee (PSC) Wrap Up

August 12 2022

FORTE Study Updates: Natural Language Processing Update

August 05 2022

NRG Oncology accepting applications for the position of Vice Chair, Radiation Oncology Committee

July 29 2022

NRG Oncology Trial Aimed to Improve Prostate Cancer Survivor Care Planning Reaches Accrual Goal

July 27 2022

Oncology Tube Conducts Interviews on NRG Oncology Research Presented During the 2022 ASCO Annual Meeting: NRG-HN002 and NRG-GI008

July 26 2022

NRG Oncology NCORP Trial of Hippocampal Avoidance for Small Cell Lung Cancer Patients Receiving Prophylactic Cranial Irradiation Reaches Accrual Goal

July 19 2022

NRG Oncology Appoints Several New Committee Chairs & Vice Chairs

July 13 2022

Adding Stereotactic Radiation Therapy to Immune Therapy for Patients with Advanced Renal Cell Cancer (NRG-GU012, The “SAMURAI” Study)

July 13 2022

IACRN: International Association of Clinical Research Nurses

July 13 2022

NRG NCORP Selects CCDR Pilot Project Awardee

July 13 2022

Join FORTE at the NRG Oncology Semiannual Meeting!

July 12 2022

NRG Oncology Accepting Applications for Radiation Oncology Committee Chair Position

July 08 2022

NRG Oncology Study of Atezolizumab and Chemoradiation for Patients with Limited-Stage Small Cell Lung Cancer Completes Accrual

June 29 2022

PSA-Based Endpoints Should Not Be Used as Surrogate Endpoints for Overall Survival in Men with Recurrent Prostate Cancer at this Time

June 28 2022

Joint Final Report of Phase III trials Demonstrate Positive Outcomes from Combination of PCV Chemotherapy and RT in Patients with Anaplastic Oligodendroglial Tumors

June 27 2022

Additional Taxane Maintenance Therapy Does Not Successfully Improve Overall Survival for Women with Advanced Ovarian, Peritoneal, and Tubal Cancers

June 08 2022

The Vision of Remote Auditing and Monitoring

June 08 2022

NRG-CC005 (FORTE) Breaking News! Welcome to the FORTE Education and Communication Specialist

May 12 2022

NRG Oncology NCORP Accepting Applications for NRG Meeting Travel Awards: Deadline May 26, 2022

May 11 2022

Preparing for the NRG Quality Assurance Audit

May 11 2022

FORTE STUDY UPDATE: NRG-CC005/FORTE Trial Communications

May 11 2022

A Randomized Phase II Trial of Immunotherapy with Dual Immune Checkpoint Inhibitors Compared to Anti-PD1 Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (NRG-GY025)

May 11 2022

A Study Champion Perspective: Christina Henson, MD

May 11 2022

Upcoming Trial Highlight: Studying Stereotactic Radiosurgery Before Versus After Surgery for Patients with Resectable Brain Metastases (NRG-BN012)

May 11 2022

NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy

May 11 2022

A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)

May 09 2022

NRG Oncology Study of Photon Versus Proton Therapy for Patients with Newly Diagnosed Glioblastoma Completes Accrual

May 09 2022

NRG Oncology Board of Directors Member, Dr. Priya Rastogi named NSABP Foundation CEO

April 29 2022

NRG Oncology Executive Director is Stepping Down from the Position

April 29 2022

NRG NCORP is Soliciting PILOT Projects Focused on Biospecimens and Clinical Trial Data: Breast Cancer Prevention Studies

April 29 2022

DEADLINE APRIL 29TH: NRG Oncology seeks to fill the position of Chair, NRG Oncology Surgical Oncology Committee

April 19 2022

West Valley Ovarian Cancer Alliance Gifts Generous Donation to the NRG Oncology Under-Represented Minority Investigator Program

April 13 2022

DEADLINE EXTENDED: NRG Oncology seeks to fill the position of Chair, NRG Oncology Immunotherapy Subcommittee

April 12 2022

FORTE STUDY UPDATE: NRG-CC005 (The FORTE Study)

April 12 2022

Testing ctDNA as a Biomarker for Adjuvant Therapy Intensity in Stage 3 Colon Cancer (NRG-GI008, The “CIRCULATE-US” Study)

April 12 2022

April is National Cancer Control Month: NRG Protocol Support Committee Column

April 12 2022

Exploring Options to Potentially Improve Treatment and Quality of Life for Patients in Two Head and Neck Cancer Trials

April 11 2022

NRG Oncology Announces New Veterans Affairs and Military Treatment Facility Subcommittee, Appoints Subcommittee Chairs

April 08 2022

NRG Oncology seeks applications for Chair of the NRG Early Career New Investigators Committee

March 24 2022

Webinar: Implementation Science for Digital Health

March 18 2022

NRG Oncology Trial Indicates Using Atezolizumab with Chemoradiation is Safe and Demonstrates Signs of Immune Activation in Women with Cervical Cancer

March 18 2022

HRR Mutational Status Prognostic of Survival Outcomes in Biomarker Analysis of NRG Oncology Trial for Women with Recurrent Platinum-Sensitive Ovarian Cancer

March 16 2022

OlympiA Trial (NSABP B-55): Olaparib as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer

March 10 2022

NRG Oncology seeks to fill the position of Co-Chair, Patient Centered Outcomes Research Committee

March 08 2022

NRG Oncology PSC 2022 Winter Meeting Wrap Up

March 08 2022

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces - Rectal/Anal Cancers

March 08 2022

FORTE Study Update - March NRG Newsletter

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI005

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI008

March 08 2022

The NRG-GI004/SWOG1610, the COMMIT Study, may further improve outcomes in Metastatic Colorectal Cancer with deficiency of DNA repair (dMMR/MSI- H)

March 08 2022

Project Team Member Application - CBX-12

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

February 15 2022

2022 Symposium & Workshop: Precision Medicine Applications in Radiation Oncology

February 11 2022

The Scientific Session - February 2022

February 09 2022

NRG Oncology Announces First Participant Enrolled on FORTE NRG-CC005

February 08 2022

Dr. Miller Re-elected as Biostatistician for the NCI Uterine Task Force

February 08 2022

RECIST 1.1 Criteria Toolkit: A Resource for Success in Clinical Trials with Solid Tumor Evaluation Requirements

February 08 2022

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

February 08 2022

FORTE Study Updates (Feb 2022 Newsletter)

February 03 2022

NRG Oncology Trial Results Indicate Trametinib Should Represent the New Standard of Care for Women with Recurrent Low-Grade Serous Ovarian Cancer

January 21 2022

Trastuzumab with Chemoradiation and Surgery Does Not Improve Outcomes for Esophageal Cancer Patients, Trial Highlights Future Research Opportunities

January 12 2022

It’s All in the DETAILS!

January 12 2022

Moving Research Forward through Legislative Advocacy

January 12 2022

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009, the “PREDICT-RT” Trial)

January 12 2022

Phase 2 Double-Blinded Trial Combining Oligometastatic Radiotherapy with Androgen Deprivation Therapy (NRG-GU011)

January 12 2022

NRG-CC005 “FORTE” Amendment #3 is Now Active

January 12 2022

A Message from the Chairs of NRG Oncology’s Research Strategy Committee, 2021: The Year in Review

January 12 2022

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer – Outcomes Presented Soon! (NRG-GY017)

January 11 2022

NRG Oncology Trial Data Concludes Paclitaxel and Carboplatin Should be Considered the Standard of Care as First-line Treatment for Women with Uterine Carcinosarcoma

December 20 2021

Barbara Good, PhD, to Retire from NRG Oncology and the NSABP Foundation

December 10 2021

Bupropion Does Not Improve Sexual Desire for Female Cancer Survivors on NRG Oncology Clinical Study

December 09 2021

Get to Know the Protocol Support Committee (PSC)

December 09 2021

Why Should We Participate in NRG-CC005/FORTE?

December 09 2021

Phase 3 Trial Combining Two Alkylating Agents with Radiotherapy for Newly Diagnosed Glioblastoma (NRG-BN011)

December 09 2021

Phase 3, Node-Positive Prostate Cancer Trial Reactivates Following Change to Experimental Treatment Arm (NRG-GU008, the INNOVATE trial)

December 06 2021

Winter 2021 Holiday Hours

December 01 2021

NRG Oncology Non-Small Cell Lung Cancer Trial Completed Accrual to Phase 2, Undergoing Data Analysis to Determine Reopening for Phase 3

December 01 2021

Annual Call for NRG Oncology Administrative Committee Member Applications

November 23 2021

Machtay Young Investigator Travel Award (Winter 2022 NRG Meeting)

November 16 2021

NRG Oncology Seeks Applicants for the Veterans Affairs/Military Treatment Facility Subcommittee Chair Position

November 11 2021

Mei-Yin C. Polley, PhD Re-elected to Serve as the Biostatistician on the NCI Head & Neck Steering Committee

November 11 2021

Background: National Coverage Analysis

November 11 2021

The NRG-CC005 (FORTE) Trial has Activated!

November 11 2021

Comparing High- and Low-Dose Cisplatin for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

November 11 2021

New Prostate Cancer Study Testing Higher-intensity Treatment for Patients with Higher Gene Risk Scores and Lower-intensity Treatment for Patients with Lower Gene Risk Scores (NRG-GU010, the GUIDANCE trial)

November 11 2021

The University of Michigan T32 in Cancer Care Delivery Accepts First Cohort of Pre- and Post- Doctoral Scholars

November 11 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

November 11 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

November 11 2021

Combining Radiotherapy and Immunotherapy in Patients with Extensive Stage Small Cell Lung Cancer (NRG-LU007, “the RAPTOR Trial”)

October 25 2021

Hypofractionated Post-Operative Prostate Bed Radiotherapy Does Not Increase Patient-Reported Toxicity for Men with Prostate Cancer

October 25 2021

Total Androgen Suppression with Dose-Escalated Radiotherapy Does Not Improve Overall Survival in Men with Intermediate-Risk Prostate Cancer: Results Highlight Need for Biomarker Studies

October 14 2021

HEAL Initiative: Advancing Health Equity in Pain Management - NOTIFY NRG BY 10/31/21

October 12 2021

Amendment to address accrual barriers for NRG-BR004 is activated

October 12 2021

Remote Audits – What is working and what is still missing

October 12 2021

Former Gynecologic Oncology Group Co-Chair, Dr. Franco Muggia, dies at 85

October 12 2021

NCI-Sponsored Trials Have Added 14-Million Years of Life for Cancer Patients

October 12 2021

Congratulations to the NRG Oncology NCORP Members Assigned to NCI Steering Committees

October 12 2021

Stewart Anderson retires from University of Pittsburgh

October 12 2021

Jim Dignam Receives the SPAIG Award

October 12 2021

Assessing the Maximum-Tolerated Dose of AMG 232 (KRT-232) with Concurrent Radiotherapy in the Treatment of Soft Tissue Sarcoma with Wild-Type P53 Gene (NRG-DT001)

October 12 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

October 07 2021

NSABP and RTOG Foundations Join GOG Foundation in Funding of the NRG Oncology Health Equity New Investigator Mentor Program

October 06 2021

NRG Oncology Launches FORTE, a Colorectal Cancer Prevention Clinical Trial

September 27 2021

Breast Radiation following Lumpectomy Confirmed to Reduce Incidence of IBR for “Good Risk” DCIS

September 14 2021

Getting Started with Radiation Therapy (RT) Credentialing (September 2021 Newsletter)

September 14 2021

NRG-CC005 (FORTE): Five- or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (September 2021 Newsletter)

September 14 2021

NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority (URM) Scholars (September 2021 Newsletter)

September 14 2021

OvCa Survivors and Thrivers Make Remarkable Strides in Research (Sept 2021 Newsletter)

September 14 2021

Highlighting NRG Gynecologic Studies: Gynecologic Cancer Awareness Month (Sept 2021 Newsletter)

August 27 2021

NRG Oncology Appoints Dr. Sue Yom as New Head and Neck Cancer Committee Chair

August 24 2021

Survival Benefits Not Seen with Addition of Metformin to Concurrent Chemoradiation in Patients with Locally Advanced Non-Small Cell Lung Cancer

August 13 2021

NRG Oncology Limited-Stage Small Cell Lung Cancer Trial Participant Interviewed on his Journey

August 13 2021

Opinion: Adoption of Clinical Research Competencies can Set the Stage for Research Success

August 13 2021

Assessing the Maximum-Tolerated Dose and the Efficacy of Tocilizumab and Atezolizumab in the Treatment of Recurrent Glioblastoma (NRG-BN010)

August 13 2021

Testing Durvalumab, Olaparib, and Cediranib in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (NRG-GY023)

August 13 2021

NRG Oncology Director of Administration, Meetings, and Exhibits, Denise Mackey, Retires After 38 Years

August 13 2021

Outstanding NRG Oncology Researcher to Receive 2021 PA Breast Cancer Coalition Potamkin Prize

August 13 2021

NRG Oncology Board of Directors Member, Dr. Jeff Michalski, Named ASTRO President-elect

July 22 2021

NRG Oncology Plenary Session with Keynote Speaker Dr. Philip E. Castle

All News

Introducing SDMC Statistics Division Member, Eric Polley, Ph.D.

Spotlight on the PSC Working Groups

FORTE Study Update: May 2023

Not Leaving Veterans Behind

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (NRG-CC009)

Should SRS be Delivered Before or After Surgery for Patients with Brain Metastases? (NRG-BN012)

NRG Oncology Seeks to Fill the Position of Vice-Chair, NRG Oncology NCORP Cancer Control Committee

Patient-Reported Outcomes from an NRG Oncology Study of Androgen Deprivation Therapy with Dose-Escalated Radiotherapy for Intermediate-Risk Prostate Cancer Show No Clinically Meaningful Differences in Scores at One Year Post-Treatment

NRG Oncology Trial Does Not Improve Overall Survival, but Shows Improvements in Several Clinical Outcomes for Men with Intermediate-Risk Prostate Cancer

NRG Oncology Study Results Confirm Conventional External Beam Radiotherapy Should Remain Standard of Care in Treating Localized Vertebral Metastases of the Spine

Webinar: NRG-GI004 / SWOG S1610 COMMIT Study Amendment 9 Overview

Show Me the Money

FORTE at #NRG2023!

Comparing Selumetinib and Olaparib to Selumetinib Alone for Ovarian and Endometrial Cancers with RAS Pathway Mutations (EAY191-N4, A ComboMATCH Treatment Trial)

Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone-Receptor Positive Metastatic Breast Cancer (EAY191-N2, A ComboMATCH Treatment Trial)

WVOCA Donates Additional Funds to the NRG Oncology Health Equity Fellowship Program

PI Perspective: The Journey of NRG-GY018

NRG Oncology and RTOG Foundation Integrated Efforts in the Head and Neck Cancer Committee

Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-positive Salivary Gland Cancer (NRG-HN010)

Webinar: Surgical Implications of ctDNA: Is this the future for colon cancer?

NRG Oncology Combined Trial Long-Term Results Indicate that Pathologic Complete Response is Prognostic of Outcomes for Soft Tissue Sarcoma Patients

Late-Breaking Results of NRG-GY018 Presented at SGO 2023: Study Demonstrates Improved PFS Outcomes with the Addition of Pembrolizumab to Chemotherapy for Women with Advanced or Recurrent Endometrial Cancer

Study Identifies Two Promising Molecular Targets for Drug Development in Recurrent and Metastatic Cervical Cancer

The Utilization of Atezolizumab as a Primer for Chemoradiation Results in Promising Immune System Alterations for Women with Locally Advanced Cervical Cancer

The Addition of Gemcitabine with Cisplatin and Intensity-Modulated Radiation Therapy Improves Outcomes for Women with Locally Advanced Vulvar Cancer

Circulating Tumor DNA: One of Our Newest Tools for Managing Solid Tumors

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

FORTE Study News: It’s Colorectal Cancer Awareness Month!

RFAs for the NRG Early Career & New Investigators (ECNI) Committee AND for the NRG ECNI Mentored Fellowship

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

NRG Oncology seeks to fill the position of Chair of the NRG Oncology Publications Committee

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology Immunotherapy Subcommittee

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

Protocol Support Committee (PSC) Column: NRG Oncology PSC 2023 Winter Meeting Wrap Up

Initial Report on Establishing Working Groups within the Head and Neck Cancer Committee

FORTE Study Update: Participant Travel Allowance

NRG Oncology Selects Three Awardees for Health Equity Fellowship Program

NRG Oncology NRG-GY018 Study Demonstrates Significantly Improved Progression Free Survival Outcomes for Women with Advanced or Recurrent Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy

Set Up for Success - Coordinating RECIST 1.1: A Community Hospital Perspective

#FORTEStudy Workshop

NRG Innovations Continue in Cancer Care Delivery Research

Adding Atezolizumab to Cisplatin and Radiotherapy for Node-Positive Locally Advanced Cervical Cancer (NRG-GY017)

A Message from the NRG Oncology Research Strategy Committee Chairs: 2022: The Year in Review

A Message from the NRG Oncology Group Chairs: 2022 in Review and a Look Ahead

NRG Oncology Holiday Closures for 2022

NRG Meeting PSC Information

NRG-CC005/FORTE Site Implementation Guide: Part 1

Julian Hong, M.D., M.S.: Steward of Cancer Care Delivery Research and Innovation

NRG Oncology Announces Leadership of New Diversity, Equity, and Inclusion Committee, New Vice Chair for Ancillary Projects Committee

Protocol Support Committee Column: NRG Best Practice Tool

Dr. Jong H. Jeong Joins NRG Oncology SDMC

#FORTEStudy is on YouTube!

Assessing SBRT to the Primary Tumor Followed by Conventional Radiation Therapy with Concurrent Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

Assessing the Addition of IMPRINT to Surgery and Systemic Therapy for Malignant Pleural Mesothelioma (NRG-LU006)

NRG Oncology Patient Advocate Committee - Call for Candidates

Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard

NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research

Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer

The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival

The Protocol Support Committee (PSC) Wants You!

#FORTEStudy in Chicago!

Comparing Docetaxel and Trastuzumab to Ado-Trastuzumab Emtansine for HER2-positive Salivary Gland Cancer (NRG-HN010)

Assessing the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (NRG-CC010)

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

NRG-BR007 (“DEBRA”): A Phase III Clinical Trial Evaluating the De-escalation of Breast Radiation for a More Conservative Treatment of Patients With Low-Risk, Hormone-Sensitive, Node-Negative Breast Cancer

NRG Oncology Appoints Chair & Vice Chair of Radiation Oncology Committee

Foundation Accrual Credit for NRG Membership Requirements Announcement

Intensity Modulated Radiotherapy Improved Patient-Reported Outcomes on NRG Oncology Clinical Trial

In Memoriam: James Lloyd Hoehn, MD, FACS

Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022

NRG Health Equity Fellowship Call for Applications

Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)

Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer

NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

Testing the addition of trastuzumab or trastuzumab/pertuzumab to the usual chemotherapy for HER2 positive uterine serous or carcinosarcoma (NRG-GY026)

NRG Oncology accepting applications for the position of Vice Chair, Ancillary Projects Committee

NRG Oncology and The GOG Foundation Honor the Life of Mary "Dicey" Scroggins